Get started
Author

Vera Heuer

Observed name: V. Heuer
OpenAlex ID: A5024515654
Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial
2023 · Sylvie Lorenzen, Thorsten Oliver Götze, et al. · Journal of Clinical Oncology · 237
Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
2022 · Salah-Eddin Al-Batran, Sylvie Lorenzen, et al. · Journal of Clinical Oncology · 99
1429P Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
2021 · S-E. Al-Batran, S. Lorenzen, et al. · Annals of Oncology · 32
Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.
2019 · Salah-Eddin Al-Batran, Claudia Pauligk, et al. · Journal of Clinical Oncology · 23
A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF-S633/DANTE trial, a trial of AIO in collaboration with SAKK.
2023 · Salah-Eddin Al-Batran, Sylvie Lorenzen, et al. · Journal of Clinical Oncology · 13
Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
2023 · Joseph Tintelnot, Alexander Stein, et al. · Frontiers in Oncology · 8
PDF
1494P Updated safety data of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma - A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK
2020 · S-E. Al-Batran, S. Lorenzen, et al. · Annals of Oncology · 7
PDF
Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1, and cT2N0 esophageal adenocarcinoma with indication for radical surgery: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group (IKF-t057/PRESTO trial).
2024 · Thorsten Goetze, Stefan Angermeier, et al. · Journal of Clinical Oncology · 4
PDF
Exploring the molecular profile of localized colon cancer: insights from the AIO Colopredict Plus registry
2024 · Ira Ekmekciu, Doreen Maria Zucha, et al. · Frontiers in Oncology · 2
PDF
1430P Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK
2021 · C. Kopp, S. Lorenzen, et al. · Annals of Oncology · 2
PDF
Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN
2021 · Kim Kricheldorf, Konstanze Döhner, et al. · Leukemia Research · 2
Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
2011 · Beate Schultheis, Henrike Neumann, et al. · International Journal of Clinical Pharmacology and Therapeutics · 2
A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK.
2024 · Salah-Eddin Al-Batran, Sylvie Lorenzen, et al. · Journal of Clinical Oncology · 1
565P Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
2023 · D.M. Gisder, I. Tischoff, et al. · Annals of Oncology
PDF
Label-free and automated approach to rapidly classify microsatellite instability (MSI) in early colon cancer (CC) analyzing the AIO ColoPredictPlus 2.0 (CPP) registry trial.
2022 · Stephanie Schörner, Frederik Großerueschkamp, et al. · Journal of Clinical Oncology
PD-11 In depth analysis of label-free infrared (IR) imaging-based microsatellite instability (MSI) classification in early colon cancer (CC) on samples from the AIO ColoPredictPlus 2.0 (CPP) registry trial
2022 · K. Gerwert, S. Schörner, et al. · Annals of Oncology
PDF
The PLATON pilot-study “Platform for analyzing targetable tumor mutations”: A PLATON network study.
2021 · Arndt Vogel, Bianca Zäpf, et al. · Journal of Clinical Oncology
Works count: 17
Citation count: 432
H-index: 7
I10-index: 5
Year
Topic
Type